{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:17:12Z","timestamp":1791472632445,"version":"4.3.4"},"reference-count":24,"publisher":"American Society for Clinical Investigation","issue":"6","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,15]]},"DOI":"10.1172\/jci168603","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T18:01:20Z","timestamp":1678816880000},"source":"Crossref","is-referenced-by-count":39,"title":["SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern"],"prefix":"10.1172","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9402-9167","authenticated-orcid":false,"given":"Arturo","family":"Casadevall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8811-195X","authenticated-orcid":false,"given":"Daniele","family":"Focosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI166032"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac802"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002390"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2003.10.018"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1086\/651022"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.7.3962-3968.2005"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq100"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2022.115656"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/science.acx9738"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005672"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.07.014"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2031364"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.03.027"},{"key":"B14","doi-asserted-by":"crossref","unstructured":"Ragonnet-Cronin M, et al. Genome-first detection of emerging resistance to novel therapeutic agents for SARS-CoV-2 [preprint]. Posted on bioRxiv July 15, 2022. https:\/\/doi.org\/10.1101\/2022.07.14.500063","DOI":"10.1101\/2022.07.14.500063"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11080823"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.28997"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910993"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.1799"},{"issue":"1","key":"B19","first-page":"96","article-title":"Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial","volume":"4","author":"Denkinger","year":"2022","journal-title":"Nat Cancer"},{"issue":"1","key":"B20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.50647","article-title":"COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis","volume":"6","author":"Senefeld","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"B21","article-title":"Analysis of anti-Omicron neutralizing antibody titers in different convalescent plasma sources","volume":"13","author":"Sullivan","year":"2022","journal-title":"medRxiv"},{"key":"B22","doi-asserted-by":"crossref","unstructured":"Sullivan DJ, et al. Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ1.1 and XBB [preprint]. Posted on bioRxiv December 16, 2022. https:\/\/doi.org\/10.1101\/2022.11.25.517977","DOI":"10.1101\/2022.11.25.517977"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.07.015"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00189-0"}],"container-title":["Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jci.org\/articles\/view\/168603\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T17:48:15Z","timestamp":1691084895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jci.org\/articles\/view\/168603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3,15]]},"published-print":{"date-parts":[[2023,3,15]]}},"alternative-id":["10.1172\/JCI168603"],"URL":"https:\/\/doi.org\/10.1172\/jci168603","relation":{},"ISSN":["1558-8238"],"issn-type":[{"value":"1558-8238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]},"article-number":"e168603"}}